These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16932680

  • 1. Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?
    Kirwan J.
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):182-3. PubMed ID: 16932680
    [No Abstract] [Full Text] [Related]

  • 2. Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis.
    Ann Intern Med; 2012 Mar 06; 156(5):I18. PubMed ID: 22393145
    [No Abstract] [Full Text] [Related]

  • 3. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 06; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 4. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
    Wassenberg S, Rau R, Steinfeld P, Zeidler H.
    Arthritis Rheum; 2005 Nov 06; 52(11):3371-80. PubMed ID: 16255011
    [Abstract] [Full Text] [Related]

  • 5. Advances in the management of rheumatoid arthritis.
    Dale J.
    Scott Med J; 2015 Aug 06; 60(3):108-14. PubMed ID: 26122283
    [Abstract] [Full Text] [Related]

  • 6. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.
    Hafström I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B, BARFOT Study Group.
    Ann Rheum Dis; 2009 Apr 06; 68(4):508-13. PubMed ID: 18420939
    [Abstract] [Full Text] [Related]

  • 7. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 06; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 8. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis.
    Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL, CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group.
    Ann Rheum Dis; 2008 May 06; 67(5):656-63. PubMed ID: 17768173
    [Abstract] [Full Text] [Related]

  • 9. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
    Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, Bratt J, van Vollenhoven RF, SWEFOT Trial Investigators Group.
    Ann Rheum Dis; 2011 Mar 06; 70(3):469-75. PubMed ID: 21149498
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and toxicity of cyclosporin A + fluocortolone + methotrexate in the treatment of rheumatoid arthritis.
    Pascalis L, Aresu G, Pia G.
    Clin Exp Rheumatol; 1999 Mar 06; 17(6):679-88. PubMed ID: 10609066
    [Abstract] [Full Text] [Related]

  • 11. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
    Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Lauridsen UB, Ellingsen T, Hansen GV, Lindegaard H, Vestergaard A, Jurik AG, Østergaard M, Hørslev-Petersen K, CIMESTRA study group.
    Ann Rheum Dis; 2008 Jun 06; 67(6):815-22. PubMed ID: 17878209
    [Abstract] [Full Text] [Related]

  • 12. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I.
    Arthritis Rheum; 2005 Nov 06; 52(11):3360-70. PubMed ID: 16255010
    [Abstract] [Full Text] [Related]

  • 13. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2000 Mar 06; 83(3):217-24. PubMed ID: 10808674
    [Abstract] [Full Text] [Related]

  • 14. Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years.
    Bijlsma JW, Jacobs JW.
    Ann N Y Acad Sci; 2014 May 06; 1318():27-31. PubMed ID: 24641732
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I, Gibson KA, Pincus T.
    Bull Hosp Jt Dis (2013); 2013 May 06; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [Abstract] [Full Text] [Related]

  • 16. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R, CareRA study group.
    Arthritis Res Ther; 2015 Apr 09; 17(1):97. PubMed ID: 25889222
    [Abstract] [Full Text] [Related]

  • 17. Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al.
    Kirwan JR.
    Arthritis Rheum; 1999 May 09; 42(5):1066-7. PubMed ID: 10323469
    [No Abstract] [Full Text] [Related]

  • 18. Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment.
    Hirata S, Kohno H, Watanabe H, Tokunaga T, Yoshida Y, Sugimoto T, Mokuda S, Oda K, Nojima T, Sugiyama E.
    Mod Rheumatol; 2021 Jul 09; 31(4):803-808. PubMed ID: 33325280
    [Abstract] [Full Text] [Related]

  • 19. [The goal for the treatment of rheumatoid arthritis should be remission].
    Möttönen T, Mäkinen H, Puolakka K.
    Duodecim; 2010 Jul 09; 126(12):1457-64. PubMed ID: 20617749
    [Abstract] [Full Text] [Related]

  • 20. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?
    Pincus T, Huizinga TW, Yazici Y.
    J Rheumatol; 2007 Feb 09; 34(2):250-2. PubMed ID: 17304647
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.